Mithra Pharmaceuticals SA (MITRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
65
About the Report
About the Report
Summary
Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women's health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the treatment of contraception and fertility, menopause and osteoporosis, gynecological infections and cancers, among others. Mithra offers its products in polymeric forms, sterile injectable products, and hormonal tablets. It also offers research, development and specialist manufacturing services. The company sells its products through a network of distributors in Belgium, France, Germany and Brazil, among others. Mithra is headquartered in Liege, Belgium.
Mithra Pharmaceuticals SA (MITRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Mithra Pharmaceuticals SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mithra Pharmaceuticals SA, Medical Devices Deals, 2012 to YTD 2018 10
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Mithra Pharma Acquires Estetrol from Pantarhei Bioscience 13
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 14
Partnerships 15
Mithra Pharma Enters into Agreement with Generic Specialty Pharma 15
Licensing Agreements 16
Pei Li Pharma Enters into Licensing Agreement with Mithra Pharma 16
Richter Gedeon Enters into Licensing Agreement with Mithra Pharma 17
Mediner Enters into Licensing Agreement with Mithra Pharma 18
Searchlight Pharma to Enter into Licensing Agreement with Mithra Pharma 19
Libbs Farmaceutica to Enter into Licensing Agreement with Mithra Pharmaceuticals 20
Fuji Pharma Enters into Licensing Agreement with Mithra Pharma for Donesta 21
Mithra Pharma Enters into Licensing Agreement for Tibelia in Canada 22
Equity Offering 23
Mithra Pharma Raises USD90 Million in Private Placement of Shares 23
Mithra Pharma Raises USD29 Million in Private Placement of Shares 25
Mithra Pharma Raises USD81.4 Million in IPO 26
Asset Transactions 27
Ceres Pharma to Acquire Women's Health Generic Business from Mithra Pharma 27
Mithra Pharmaceuticals SA-Key Competitors 28
Mithra Pharmaceuticals SA-Key Employees 29
Mithra Pharmaceuticals SA-Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Sep 25, 2018: Mithra announces 2018 half year results 31
Mar 02, 2018: Mithra Reports 2017 Annual Results 36
Sep 21, 2017: Mithra Announces 2017 Half Year Results 41
Mar 02, 2017: Mithra Pharmaceuticals: Mithra reports 2016 annual results 42
Corporate Communications 45
Mar 03, 2017: Mithra signs agreement with Fuji Pharma to commercialise Donesta 45
Jan 19, 2017: USPTO issues Notice of Allowance for Mithra's application for Estetrol patent 46
Jan 12, 2017: Mithra Pharmaceuticals sets up scientific advisory boards for Donesta 47
Jan 06, 2017: Mithra Pharmaceuticals Appoints Christophe Marechal As Chief Financial Officer 48
Government and Public Interest 49
Feb 13, 2017: Mithra Pharmaceuticals: Mithra Granted EUR 1.9 Million In Non-Dilutive Funding 49
Product News 50
01/12/2017: Mithra's North American Advisory Board For Donesta to Meet In Miami, Florida 50
Product Approvals 51
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 51
Clinical Trials 52
May 03, 2018: Mithra Announces Last Subject Visit in Estelle Phase III Study in EU/Russia and Completion of Endometrial Substudy 52
Mar 23, 2018: Mithra Announces Completion Of Estelle Cycles Required In Phase Iii Contraception Studies 53
Feb 08, 2018: Mithra Announces Very Promising Hemostasis Results for Estelle 54
Nov 30, 2017: Mithra Provides Update On Estelle Study 55
Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US & Canada 56
Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US and Canada 57
Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study 58
Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Substudy 59
Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 60
Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal 61
Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 62
May 12, 2017: Mithra to Initiate PK Study for Estelle 63
Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Figure
List of Figures
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mithra Pharmaceuticals SA, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mithra Pharmaceuticals SA, Deals By Therapy Area, 2012 to YTD 2018 9
Mithra Pharmaceuticals SA, Medical Devices Deals, 2012 to YTD 2018 10
Mithra Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mithra Pharma Acquires Estetrol from Pantarhei Bioscience 13
Mithra Pharma Acquires Women Health Portfolio from Uteron Pharma 14
Mithra Pharma Enters into Agreement with Generic Specialty Pharma 15
Pei Li Pharma Enters into Licensing Agreement with Mithra Pharma 16
Richter Gedeon Enters into Licensing Agreement with Mithra Pharma 17
Mediner Enters into Licensing Agreement with Mithra Pharma 18
Searchlight Pharma to Enter into Licensing Agreement with Mithra Pharma 19
Libbs Farmaceutica to Enter into Licensing Agreement with Mithra Pharmaceuticals 20
Fuji Pharma Enters into Licensing Agreement with Mithra Pharma for Donesta 21
Mithra Pharma Enters into Licensing Agreement for Tibelia in Canada 22
Mithra Pharma Raises USD90 Million in Private Placement of Shares 23
Mithra Pharma Raises USD29 Million in Private Placement of Shares 25
Mithra Pharma Raises USD81.4 Million in IPO 26
Ceres Pharma to Acquire Women's Health Generic Business from Mithra Pharma 27
Mithra Pharmaceuticals SA, Key Competitors 28
Mithra Pharmaceuticals SA, Key Employees 29
Mithra Pharmaceuticals SA, Subsidiaries 30
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.